The effect of Alphabodies® against human lnterleukin lL23 in the transplant model of psoriasis, in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intradermally into the transplant.

The effect of Alphabodies® against human lnterleukin lL23 in the transplant model of psoriasis, in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intradermally into the transplant. - The effect of Alphabodies® against lnterleukin lL23 in the psoriasis model

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39832

Enrollment

Registered

2013-02-04

Start date

2013-01-14

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

een onderzoek naar werking van een middel in een model. Psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with light to mild psoriasis vulgaris.

Exclusion criteria

Exclusion criteria: Volunteers cannot be treated systemically (for psoriasis) Volunteers cannot have UV/light therapy Volunteers cannot be taking immune-modulating drugs for other diseases Volunteers should not have problems with the Köbner phenomenom.

Design outcomes

Secondary

Measure	Time frame
NVT	—

Primary

Measure	Time frame
NVT	—

Countries

Netherlands

Outcome results